Dactinomycin
- Generic Name
- Dactinomycin
- Brand Names
- Cosmegen
- Drug Type
- Small Molecule
- Chemical Formula
- C62H86N12O16
- CAS Number
- 50-76-0
- Unique Ingredient Identifier
- 1CC1JFE158
Overview
A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)
Background
A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)
Indication
For the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen
Associated Conditions
- Ewing's Sarcoma
- Gestational Trophoblastic Neoplasia
- Osteosarcoma
- Ovarian Cancer
- Rhabdomyosarcomas
- Wilms' tumor
- Metastatic nonseminomatous Testicular cancer
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.